The study aimed to analyze the influence of restaging transurethral resection of bladder tumor (reTURB) timing on outcomes in patients receiving Bacillus Calmette-Guerin (BCG) immunotherapy.
This retrospective study enrolled 491 patients with bladder cancer receiving BCG intravesical therapy between 1998 and 2016. All patients were followed up for at least 12 months and received at least 7 BCG instillations. The patients were analyzed in terms of recurrence free, progression free, and cancer specific survival (CSS).
Median follow-up was 57 months (12-257 months). The risk for all analyzed clinical events was higher in patients who underwent reTURB after 6 weeks from primary TURB. After the change point of 57 days after primary resection, further delay was not associated with increased risk of recurrence and progression. The time limit for CSS was 76 days. With every 1 more day of time interval between TURB and reTURB, the risk of each clinical event in follow-up increased by 4%.
There is no benefit of the reTURB performed after 8 weeks from primary TURB. Optimal timing of reTURB is from 2 to 6 weeks after initial TURB. However, even within this time frame, the sooner the procedure is performed, the risk of recurrence, progression, or cancer-specific death is lower.
Urologia internationalis. 2018 Sep 28 [Epub ahead of print]
Wojciech Krajewski, Romuald Zdrojowy, Janusz Dembowski, Sławomir Poletajew, Michał Wróbel, Mateusz Łuczak, Andrzej Tukiendorf, Anna Kolodziej
Department of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland., Department of General, Oncological and Functional Oncology, Medical University of Warsaw, Warsaw, Poland., Department of Urology and Oncologic Urology Wrocław, Lowersilesian Specialistic Hospital, Wrocław, Poland., Department of Social Medicine, Wrocław Medical University, Wrocław, Poland.